Assessing Nektar Therapeutics (NKTR) Valuation After New Multiple Sclerosis Collaboration With UCSF [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
Nektar Therapeutics (NKTR) is back on investors' radar after announcing an academic research collaboration with the University of California, San Francisco, and leading neuroimmunologist Dr. Stephen L. Hauser focused on multiple sclerosis. See our latest analysis for Nektar Therapeutics. The collaboration news lands after a sharp 83.12% 1 month share price return and a 24.63% 3 month share price return, while the 1 year total shareholder return is very large and contrasts with a weak 5 year total shareholder return of 78.52%. If you are watching how biotech catalysts can move markets, it could be a good moment to scan 28 healthcare AI stocks as a starting point for other potential opportunities in the space. With the stock up sharply in recent months, yet still trading at a large discount to the average analyst price target of US$129.86, you have to ask: is this a fresh buying opportunity, or is the market already pricing in future growth? Most Popular Narrative: 44.6% Unde
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Does Nektar (NKTR)–UCSF MS Collaboration Hint At A Broader Neuroscience Pivot For The Company? [Yahoo! Finance]Yahoo! Finance
- Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets [Yahoo! Finance]Yahoo! Finance
- Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial MarketsPR Newswire
- Nektar Therapeutics to Participate in Two Investor Conferences in March [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics to Participate in Two Investor Conferences in MarchPR Newswire
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 2/20/26 - Form 4
- 2/20/26 - Form 4
- 2/18/26 - Form 144
- NKTR's page on the SEC website